ATE205713T1 - Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit - Google Patents

Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit

Info

Publication number
ATE205713T1
ATE205713T1 AT94200484T AT94200484T ATE205713T1 AT E205713 T1 ATE205713 T1 AT E205713T1 AT 94200484 T AT94200484 T AT 94200484T AT 94200484 T AT94200484 T AT 94200484T AT E205713 T1 ATE205713 T1 AT E205713T1
Authority
AT
Austria
Prior art keywords
agent
mast cell
drug delivery
transdermal drug
sensitizing
Prior art date
Application number
AT94200484T
Other languages
English (en)
Inventor
John Wille
Agis Kydonieus
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE205713(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE205713T1 publication Critical patent/ATE205713T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94200484T 1993-02-25 1994-02-25 Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit ATE205713T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2208093A 1993-02-25 1993-02-25

Publications (1)

Publication Number Publication Date
ATE205713T1 true ATE205713T1 (de) 2001-10-15

Family

ID=21807714

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94200484T ATE205713T1 (de) 1993-02-25 1994-02-25 Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit

Country Status (8)

Country Link
EP (1) EP0612525B1 (de)
JP (1) JPH072670A (de)
AT (1) ATE205713T1 (de)
AU (1) AU686123B2 (de)
CA (1) CA2114968A1 (de)
DE (1) DE69428295T2 (de)
MX (1) MX9401331A (de)
ZA (1) ZA94856B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
FR2719474B1 (fr) 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US5672640A (en) * 1995-07-12 1997-09-30 Caschem, Inc. Polypropylene compatible grease compositions for optical fiber cable
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
CA2200984A1 (en) * 1995-07-25 1997-02-13 Samir S. Mitragotri Enhanced transdermal transfer using ultrasound
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
FR2740040B1 (fr) 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
AU3309097A (en) * 1996-06-12 1998-01-07 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
EP0925088A2 (de) 1996-06-28 1999-06-30 Sontra Medical, L.P. Ultraschallsteigerung des transdermalen transports
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
WO2004060322A2 (en) * 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
FI20030379A0 (fi) 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus
WO2004091521A2 (en) 2003-04-10 2004-10-28 Neurogesx, Inc. Methods and compositions for administration of trpv1 agonists
FI20031793A0 (fi) * 2003-12-09 2003-12-09 Lasse Leino Uusi anti-proliferatiivinen farmaseuttinen koostumus
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8224414B2 (en) 2004-10-28 2012-07-17 Echo Therapeutics, Inc. System and method for analyte sampling and analysis with hydrogel
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
CA2615912C (en) * 2005-08-01 2013-10-01 Maruho Co., Ltd. Lotion preparation containing pyridonecarboxylic acid derivative
AU2008222757B2 (en) 2007-03-07 2011-06-09 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
RU2435616C2 (ru) 2007-04-27 2011-12-10 Эко Терапьютикс, Инк. Устройство для повышения проницаемости кожи для обнаружения аналита или трансдермальтной доставки лекарственных препаратов
JP5758587B2 (ja) * 2010-05-13 2015-08-05 智 堀越 ビニルイミダゾール類の光異性化方法
EP2729148A4 (de) 2011-07-06 2015-04-22 Parkinson S Inst Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
EP3801732A4 (de) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Verfahren und systeme zur wirkstofffreisetzung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
ATE126058T1 (de) * 1990-06-29 1995-08-15 Bode Chemie Gmbh & Co Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsäure.
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices

Also Published As

Publication number Publication date
JPH072670A (ja) 1995-01-06
AU5635094A (en) 1994-09-01
MX9401331A (es) 1994-08-31
AU686123B2 (en) 1998-02-05
EP0612525A1 (de) 1994-08-31
ZA94856B (en) 1994-09-05
DE69428295D1 (de) 2001-10-25
EP0612525B1 (de) 2001-09-19
CA2114968A1 (en) 1994-08-26
DE69428295T2 (de) 2002-06-20

Similar Documents

Publication Publication Date Title
ATE205713T1 (de) Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit
US4997853A (en) Method and compositions utilizing capsaicin as an external analgesic
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
SE8403487D0 (sv) Farmaceutisk komposition
ATE63220T1 (de) Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben.
DE1131847B (de) Mittel zur Pflege sowie zur Foerderung des Wachstums der Haut, der Haare und der Naegel
KR950703972A (ko) 항혈전성 치료 및 암 예방을 위한 아세틸살리실산을 함유하는 경피 투여 시스템(transdermal administration system containing acetylsalicyliic acid for antithrombotic therapy and the prevention of cancer)
EE9900428A (et) Köhavastased ravimkoostised
DE68912195T2 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
SE8001599L (sv) Transdermalt medicineringssystem for isosorbiddinitrat
DE68926115D1 (de) Verfahren zur behandlung von akne
ATE180969T1 (de) Pharmazeutische zusammensetzungen enthaltend urodeoxycholicsäure
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
US3510554A (en) Composition and method for hardening finger- and toenails
KR910005858A (ko) 지방산 요법
US20160184331A1 (en) Base and external preparation for skin
DE69021405D1 (de) System zur gesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu dessen Herstellung.
JPS635378B2 (de)
KR880002506A (ko) 경피성 조성물
ATE28384T1 (de) Medizinisches verfahren und zubereitung.
RU93053628A (ru) Активный ингредиент, способ его получения, композиция на его основе, способ ее приготовления
JPH01503465A (ja) 甲状腺刺激ホルモン放出ホルモン類似物を含む薬学的方法
JPS61286327A (ja) 移植皮膚処置剤
WO1988007371A3 (en) Prevention and treatment of the deleterious effects of exposing skin to the sun, and compositions therefor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties